On the other hand, tumor‐specific CD8+TRM cells generated in contexts like melanoma‐associated vitiligo have been shown to provide long‐lasting protection against metastatic melanoma, correlating with improved patient prognosis [146]. This evidence concerns the gene CD8A and melanoma.